May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
19 citations
,
September 2006 in “Journal of Neurophysiology” Neurosteroids help balance brain signals when certain inhibitions are reduced.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
34 citations
,
December 2015 in “Neuroscience & Biobehavioral Reviews” Some hormone-related drugs may protect brain cells in Parkinson's disease differently in men and women.
March 2024 in “Journal of the American Academy of Dermatology” Taking medication for hair loss might cause sexual problems.
Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.
8 citations
,
October 1998 in “Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology” Proscar (finasteride) blocks 5α-reductase in sea urchin ovaries and testes, suggesting potential treatment for androgen-related conditions.
May 2026 in “ACS Catalysis” Efficient enzyme function relies on specific residue interactions and structural coordination.
4 citations
,
July 2020 in “Research Square (Research Square)” The research helps understand how finasteride works and aids drug development.
184 citations
,
January 2000 in “European Urology” Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
November 2017 in “International journal of family & community medicine” A man's low testosterone and related symptoms improved after he stopped taking hair loss drugs.
September 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Finasteride may help reduce opioid use.
1 citations
,
June 2025 in “Cell Biochemistry and Biophysics” January 2002 in “映像情報メディア学会技術報告” Some prostate cancers have gene changes that may affect treatment with certain drugs.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
May 2024 in “European urology focus” Drugs for prostate enlargement and hair loss were not linked to increased risk of depression or suicide.
4 citations
,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.
90 citations
,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
9 citations
,
August 2000 in “Journal of Periodontal Research” Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.
12 citations
,
March 1995 in “Journal of the American Chemical Society” Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.
Finasteride and dutasteride can harm male reproductive health, affecting sperm and causing sexual dysfunction.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
51 citations
,
July 2013 in “Brain Research” Testosterone needs to be converted to DHT to reduce stress response in male rats.
September 2025 in “Journal of the American Academy of Dermatology” Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.